Mexico could benefit from upgraded intellectual property rules to become a regional biotech hub, write Alberto Saracho and Philip Stevens.
Philip founded Geneva Network in 2015.
His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues.
Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant.
He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK).
He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.
The delinkage agenda under discussion in Geneva, while well-intentioned, is a distraction from practical solutions to increase access to medicines.
Understanding how exactly these structurally similar molecules work on the human body requires significant investments of time, money and expertise, write Jack Ellis and Philip Stevens.
Patents are necessary to incentivise research into this vital area of medicine, write Philip Stevens and Jack Ellis
Combining different drugs into a single pill can have enormous therapeutic benefits but research and development is difficult and costly, write Philip Stevens and Jack Ellis
Improving access to innovative medicines will deliver social and economic benefits, writes Philip Stevens.
Global IP rules need a refresh to take account of rapidly changing technology, write Philip Stevens and Nigel Cory.
Alors que les populations sud africaines ont un besoin cruel de médicaments, les nouveaux médicaments…
The European Commission is undermining innovation on the continent through its contradictory policy making around innovation.